Serina Therapeutics, a clinical-stage biotech firm, has announced the advancement of SER-270, a once-weekly injectable treatment for tardive dyskinesia (TD). The novel drug leverages Serina’s proprietary POZ polymer technology, offering an alternative to current oral VMAT2 inhibitors.
What is SER-270?
- SER-270 is a POZ-conjugated VMAT2 inhibitor.
- Designed for subcutaneous weekly administration.
- Targets patients struggling with daily medication adherence, especially those on long-acting injectable (LAI) antipsychotics.
Tardive dyskinesia is a serious, underdiagnosed movement disorder linked to long-term antipsychotic use. Most affected individuals have chronic psychiatric conditions like schizophrenia or bipolar disorder.
- <30% of TD patients in the U.S. are diagnosed.
- Fewer than half of those receive treatment.
- The TD drug market surpassed $3.7B in 2024 and is expected to grow to $5.4B by 2030.
SER-270 Targets Key Gaps in Current TD Care
POZ-VMAT2i offers a differentiated solution:
- Once-weekly injection: Ideal for patients non-compliant with daily pills.
- Better fit for institutions: Eases logistical challenges for caregivers.
- Non-oral: Supports patients with dysphagia, including the elderly and neurologically impaired.
Expansion Potential: Huntington’s Disease
Serina plans to evaluate SER-270 for chorea in Huntington’s disease. Many patients in this population struggle with swallowing, making injectables more practical than oral drugs.
Leadership Perspective
“POZ-VMAT2i solves real-world barriers—non-compliance, institutional care, and swallowing issues. It’s about expanding access and improving lives.”
- Steve Ledger, CEO of Serina Therapeutics
About Serina Therapeutics
Serina is developing a pipeline of drug candidates using its POZ Platform to improve delivery, dosing, and patient adherence, primarily for neurological diseases and movement disorders.
